<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2016-10-17" updated="2019-12-02">
  <drugbank-id primary="true">DB11624</drugbank-id>
  <name>Epoetin delta</name>
  <description>Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.</description>
  <cas-number>261356-80-3</cas-number>
  <unii>474EI5756Y</unii>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Dynepo</name>
      <labeller>Shire Pharmaceutical Contracts Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000372</ema-product-code>
      <ema-ma-number>EU/1/02/211/001</ema-ma-number>
      <started-marketing-on>2002-03-18</started-marketing-on>
      <ended-marketing-on>2009-04-23</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1000 IU</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Dynepo</name>
      <labeller>Shire Pharmaceutical Contracts Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000372</ema-product-code>
      <ema-ma-number>EU/1/02/211/002</ema-ma-number>
      <started-marketing-on>2002-03-18</started-marketing-on>
      <ended-marketing-on>2009-04-23</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2000 IU</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Dynepo</name>
      <labeller>Shire Pharmaceutical Contracts Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000372</ema-product-code>
      <ema-ma-number>EU/1/02/211/003</ema-ma-number>
      <started-marketing-on>2002-03-18</started-marketing-on>
      <ended-marketing-on>2009-04-23</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>3000 IU</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Dynepo</name>
      <labeller>Shire Pharmaceutical Contracts Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000372</ema-product-code>
      <ema-ma-number>EU/1/02/211/004</ema-ma-number>
      <started-marketing-on>2002-03-18</started-marketing-on>
      <ended-marketing-on>2009-04-23</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4000 IU</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Dynepo</name>
      <labeller>Shire Pharmaceutical Contracts Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000372</ema-product-code>
      <ema-ma-number>EU/1/02/211/005</ema-ma-number>
      <started-marketing-on>2002-03-18</started-marketing-on>
      <ended-marketing-on>2009-04-23</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10000 IU</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Dynepo</name>
      <labeller>Shire Pharmaceutical Contracts Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000372</ema-product-code>
      <ema-ma-number>EU/1/02/211/010</ema-ma-number>
      <started-marketing-on>2002-03-18</started-marketing-on>
      <ended-marketing-on>2009-04-23</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5000 IU</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Dynepo</name>
      <labeller>Shire Pharmaceutical Contracts Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000372</ema-product-code>
      <ema-ma-number>EU/1/02/211/011</ema-ma-number>
      <started-marketing-on>2002-03-18</started-marketing-on>
      <ended-marketing-on>2009-04-23</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>6000 IU</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Dynepo</name>
      <labeller>Shire Pharmaceutical Contracts Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000372</ema-product-code>
      <ema-ma-number>EU/1/02/211/012</ema-ma-number>
      <started-marketing-on>2002-03-18</started-marketing-on>
      <ended-marketing-on>2009-04-23</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>8000 IU</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Dynepo</name>
      <ingredients>Epoetin delta</ingredients>
    </mixture>
    <mixture>
      <name>Dynepo</name>
      <ingredients>Epoetin delta</ingredients>
    </mixture>
    <mixture>
      <name>Dynepo</name>
      <ingredients>Epoetin delta</ingredients>
    </mixture>
    <mixture>
      <name>Dynepo</name>
      <ingredients>Epoetin delta</ingredients>
    </mixture>
    <mixture>
      <name>Dynepo</name>
      <ingredients>Epoetin delta</ingredients>
    </mixture>
    <mixture>
      <name>Dynepo</name>
      <ingredients>Epoetin delta</ingredients>
    </mixture>
    <mixture>
      <name>Dynepo</name>
      <ingredients>Epoetin delta</ingredients>
    </mixture>
    <mixture>
      <name>Dynepo</name>
      <ingredients>Epoetin delta</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Colony-Stimulating Factors</category>
      <mesh-id>D003115</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Glycoconjugates</category>
      <mesh-id>D006001</mesh-id>
    </category>
    <category>
      <category>Glycoproteins</category>
      <mesh-id>D006023</mesh-id>
    </category>
    <category>
      <category>Hematopoietic Cell Growth Factors</category>
      <mesh-id>D016298</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>1000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>2000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>3000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>4000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>5000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>6000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>8000 IU</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of pulmonary toxicity can be increased when Epoetin delta is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05168</drugbank-id>
      <name>Vintafolide</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vintafolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinflunine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vincamine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers/>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>